【摘要】 目的评价吉非替尼(Gefitinib)治疗晚期肺腺癌的疗效及毒副反应。方法对55例化疗失败或不宜化疗的Ⅳ期肺腺癌患者给予吉非替尼口服250mg/d,至病情进展或出现不可耐受的不良反应。结果55例患者中无CR患者,PR21例(38.2%),SD15例(27.3%),疾病控制率(DCR=CR+PR+SD)65.5%,PD19例(34.5%)。中位肿瘤进展时间(TTP)为7.2月,1年生存率为43.6%。与药物相关的不良反应依次为痤疮样皮疹28例(50.9%),皮肤干燥19例(34.5%),腹泻14例(25.5%),恶心7例(12.7%),肝功能异常(ALT,AST升高)1例(1.8%)。结论吉非替尼治疗晚期肺腺癌有效,毒副反应轻微,患者依从性和耐受性好。更多还原

【Abstract】 Objective To evaluate the efficacy and toxicity of Gefitinib in the treatment of advanced adenocarcinoma of lung. Methods Fifty-five patients with stage Ⅳadenocarcinoma of the lung who had failed or not tolerated or refused chemotherapy received 250mg oral doses of Gefitinib once a day,until disease progression or development to intolerable toxic reaction. Results There was no complete regression observed,partial response(PR) rate was 38.2%(21/55),stable disease (SD)27.3% (15/55),disease control rate (CR+PR+SD)65.5%,progression of disease(PD) 34.5%(19/55) and median time to tumor progression(TTP) was 7.2 month. One-year survival rate was 43.6%.The drug-related adverse reactions were skin rash 28(50.9%),dry skin 19(34.5%),diarrhea 14(25.5%),nausea 7(12.7%),and hepatic dysfunction (ALT and AST increase) 1 (1.8%). Conclusion Gefitinib is active in patients with advanced adenocarcinoma of lung. It is well tolerated with minimal side-effects. All patients have well compliance and tolerability.更多还原